secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-07-30T01:49:15+00:00
Accession:  0001104659-26-088380
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma believes it meets Nasdaq equity minimum after InnocsAI merger
------------------------------------------------------------------------------

- Company believes stockholders' equity now exceeds $2.5 million following merger with InnocsAI LLC.
- Awaiting Nasdaq compliance determination; Nasdaq will continue to monitor compliance.
- If next periodic report does not show compliance, Company may face future delisting.
- Merger with InnocsAI LLC previously announced; no further deal terms disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926088380/0001104659-26-088380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926088380/tm2621658d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer